Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Eikon Therapeutics, Inc. (EIKN) had Normalized Income after Taxes of -82.96M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
-82.96M |
|
-- |
|
-- |
|
87.34M |
|
-87.34M |
|
4.38M |
|
-82.96M |
|
-82.96M |
|
-82.96M |
|
-82.96M |
|
-82.96M |
|
|
Normalized Income after Taxes |
-82.96M |
-87.34M |
|
-82.22M |
|
33.70M |
|
33.70M |
|
-2.46 |
|
-2.46 |
|
| Balance Sheet Financials | |
529.50M |
|
138.07M |
|
321.32M |
|
850.83M |
|
45.06M |
|
-- |
|
255.09M |
|
300.15M |
|
550.67M |
|
550.67M |
|
550.67M |
|
54.14M |
|
| Cash Flow Statement Financials | |
-89.80M |
|
-203.22M |
|
349.31M |
|
113.07M |
|
169.36M |
|
56.29M |
|
2.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-90.06M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.06% |
|
-15.06% |
|
-9.75% |
|
-15.06% |
|
10.17 |
|
-2.67 |
|
-2.66 |
|